TY  - CHAP
M1  - Book, Section
TI  - Chronic Leukemias and Multiple Myeloma
A1  - Pick, Amy M.
A1  - Matya, Jared E.
A2  - Chisholm-Burns, Marie A.
A2  - Schwinghammer, Terry L.
A2  - Malone, Patrick M.
A2  - Kolesar, Jill M.
A2  - Bookstaver, P. Brandon
A2  - Lee, Kelly C.
PY  - 2022
T2  - Pharmacotherapy Principles & Practice, 6e
AB  - LEARNING  OBJECTIVESUpon  completion  of  the  chapter,  the  reader  will  be  able  to:Explain  the  role  of  the  Philadelphia  chromosome  in  the  pathophysiology  of  chronic  myelogenous  leukemia  (CML).Identify  the  clinical  signs  and  symptoms  and  laboratory  findings  associated  with  CML,  chronic  lymphocytic  leukemia  (CLL),  and  multiple  myeloma  (MM).Discuss  first-  and  second-line  treatment  options  for  CML,  including  options  for  those  patients  with  drug-resistant  disease.Describe  the  clinical  course  of  CLL  and  distinguish  which  patients  may  be  observed  and  who  require  treatment.Compare  the  treatment  options  available  for  CLL,  noting  treatment  differences  based  on  the  drug’s  toxicity  profile.Describe  the  clinical  presentation  and  symptoms  of  MM.Recommend  the  appropriate  treatment  for  patients  with  MM,  recognizing  the  importance  of  combination  therapy  and  the  role  of  autologous  hematopoietic  stem-cell  transplant.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/10/06
UR  - ppp.mhmedical.com/content.aspx?aid=1187023108
ER  -